These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 30149904)
21. Imidazole Derivatives as Promising Agents for the Treatment of Chagas Disease. de Araújo JS; García-Rubia A; Sebastián-Pérez V; Kalejaiye TD; Bernardino da Silva P; Fonseca-Berzal CR; Maes L; De Koning HP; Soeiro MNC; Gil C Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670432 [TBL] [Abstract][Full Text] [Related]
22. Trypanothione Reductase: A Target for the Development of Anti- Trypanosoma cruzi Drugs. Vázquez K; Paulino M; Salas CO; Zarate-Ramos JJ; Vera B; Rivera G Mini Rev Med Chem; 2017; 17(11):939-946. PubMed ID: 28302040 [TBL] [Abstract][Full Text] [Related]
23. In vitro evaluation of arylsubstituted imidazoles derivatives as antiprotozoal agents and docking studies on sterol 14α-demethylase (CYP51) from Trypanosoma cruzi, Leishmania infantum, and Trypanosoma brucei. Rojas Vargas JA; López AG; Pérez Y; Cos P; Froeyen M Parasitol Res; 2019 May; 118(5):1533-1548. PubMed ID: 30903349 [TBL] [Abstract][Full Text] [Related]
24. Chagas disease drug discovery: toward a new era. Chatelain E J Biomol Screen; 2015 Jan; 20(1):22-35. PubMed ID: 25245987 [TBL] [Abstract][Full Text] [Related]
25. Bisphosphonate-Based Molecules as Potential New Antiparasitic Drugs. Branco Santos JC; de Melo JA; Maheshwari S; de Medeiros WMTQ; de Freitas Oliveira JW; Moreno CJ; Mario Amzel L; Gabelli SB; Sousa Silva M Molecules; 2020 Jun; 25(11):. PubMed ID: 32503272 [TBL] [Abstract][Full Text] [Related]
26. Recent Advances in the Discovery of Antiparasitic Drugs for Chagas Disease and Malaria. de Moraes J Curr Top Med Chem; 2023; 23(3):158. PubMed ID: 36919344 [No Abstract] [Full Text] [Related]
30. Phosphonium lipocations as antiparasitic agents. Long TE; Lu X; Galizzi M; Docampo R; Gut J; Rosenthal PJ Bioorg Med Chem Lett; 2012 Apr; 22(8):2976-9. PubMed ID: 22414614 [TBL] [Abstract][Full Text] [Related]
31. Recent developments in trans-sialidase inhibitors of Trypanosoma cruzi. Kashif M; Moreno-Herrera A; Lara-Ramirez EE; Ramírez-Moreno E; Bocanegra-García V; Ashfaq M; Rivera G J Drug Target; 2017 Jul; 25(6):485-498. PubMed ID: 28140698 [TBL] [Abstract][Full Text] [Related]
32. Trypanothione Reductase and Superoxide Dismutase as Current Drug Targets for Trypanosoma cruzi: An Overview of Compounds with Activity against Chagas Disease. Beltran-Hortelano I; Perez-Silanes S; Galiano S Curr Med Chem; 2017 May; 24(11):1066-1138. PubMed ID: 28025938 [TBL] [Abstract][Full Text] [Related]
33. A flow cytometer-based method to simultaneously assess activity and selectivity of compounds against the intracellular forms of Trypanosoma cruzi. Miranda CG; Solana ME; Curto MLA; Lammel EM; Schijman AG; Alba Soto CD Acta Trop; 2015 Dec; 152():8-16. PubMed ID: 26272680 [TBL] [Abstract][Full Text] [Related]
34. Novel drug discovery for Chagas disease. Moraes CB; Franco CH Expert Opin Drug Discov; 2016; 11(5):447-55. PubMed ID: 26967915 [TBL] [Abstract][Full Text] [Related]
35. WC-9 a Lead Drug with Great Prospects for American Trypanosomiasis and Toxoplasmosis. Rodriguez JB Mini Rev Med Chem; 2016; 16(15):1195-1200. PubMed ID: 27290911 [TBL] [Abstract][Full Text] [Related]
36. Design, synthesis and molecular docking studies of novel N-arylsulfonyl-benzimidazoles with anti Trypanosoma cruzi activity. Miana GE; Ribone SR; Vera DMA; Sánchez-Moreno M; Mazzieri MR; Quevedo MA Eur J Med Chem; 2019 Mar; 165():1-10. PubMed ID: 30641409 [TBL] [Abstract][Full Text] [Related]
37. Structural investigation of Trypanosoma cruzi Akt-like kinase as drug target against Chagas disease. Stadler KA; Ortiz-Joya LJ; Singh Sahrawat A; Buhlheller C; Gruber K; Pavkov-Keller T; O'Hagan TB; Guarné A; Pulido S; Marín-Villa M; Zangger K; Gubensäk N Sci Rep; 2024 May; 14(1):10039. PubMed ID: 38693166 [TBL] [Abstract][Full Text] [Related]
38. Phenotypic screening as a strategic component of drug discovery programs targeting novel antiparasitic and antimycobacterial agents: an editorial. Butera JA J Med Chem; 2013 Oct; 56(20):7715-8. PubMed ID: 23927625 [TBL] [Abstract][Full Text] [Related]
39. Tropical and Subtropical Parasitic Diseases: Targets for a New Approach to Virtual Screening. Yunta MJR; Dietrich RC Mol Inform; 2019 Nov; 38(11-12):e1900052. PubMed ID: 31490642 [TBL] [Abstract][Full Text] [Related]
40. Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration. Ferreira de Almeida Fiuza L; Peres RB; Simões-Silva MR; da Silva PB; Batista DDGJ; da Silva CF; Nefertiti Silva da Gama A; Krishna Reddy TR; Soeiro MNC Eur J Med Chem; 2018 Apr; 149():257-268. PubMed ID: 29501946 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]